Global RNA-Based Therapeutics and Vaccines Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
- SKU ID : GIR-GIR1809170098 13120544
- |
- Publishing Date: 12-Nov-2018
- |
- Region: Global
- |
- No. of pages: 117
RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.
Scope of the Report:
This report studies the RNA-Based Therapeutics and Vaccines market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the RNA-Based Therapeutics and Vaccines market by product type and applications/end industries.
RNA-based biopharmaceuticals are a relatively new class of therapies that are demonstrating significant growth and potential for the treatment and prevention of chronic and rare diseases.
The global RNA-Based Therapeutics and Vaccines market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of RNA-Based Therapeutics and Vaccines.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
RNA-Based Therapeutics
RNA-Based Vaccines
Market Segment by Applications, can be divided into
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
Scope of the Report:
This report studies the RNA-Based Therapeutics and Vaccines market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the RNA-Based Therapeutics and Vaccines market by product type and applications/end industries.
RNA-based biopharmaceuticals are a relatively new class of therapies that are demonstrating significant growth and potential for the treatment and prevention of chronic and rare diseases.
The global RNA-Based Therapeutics and Vaccines market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of RNA-Based Therapeutics and Vaccines.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
RNA-Based Therapeutics
RNA-Based Vaccines
Market Segment by Applications, can be divided into
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
